首页> 美国卫生研究院文献>Nanomaterials >Encapsulation of 16-Hydroxycleroda-313-Dine-1615-Olide in Mesoporous Silica Nanoparticles as a Natural Dipeptidyl Peptidase-4 Inhibitor Potentiated Hypoglycemia in Diabetic Mice
【2h】

Encapsulation of 16-Hydroxycleroda-313-Dine-1615-Olide in Mesoporous Silica Nanoparticles as a Natural Dipeptidyl Peptidase-4 Inhibitor Potentiated Hypoglycemia in Diabetic Mice

机译:糖尿病小鼠中的天然二肽基肽酶-4抑制剂增强的中孔硅胶纳米颗粒中的16-羟基闭环菌素313-Dine-1615-Olide的封装。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Natural supplements comprise good efficacy with less adverse effects as against diabetic therapy, but their advancement as anti-diabetic agents is unsatisfactory with regard to the delivery system. Dipeptidyl peptidase-4 (DPP4)/CD26) can degrade glucagon-like pepetide-1 (GLP-1) which renders a decrease of blood glucose levels. 16-hydroxycleroda-3,13-dine-16,15-olide (HCD) extracted from Polyalthia longifolia, exhibits numerous medicinal potentials including hypoglycemic potential. On consideration of HCD application, the bioavailability is affected by low solubility. Extended experiments of anti-diabetic efficacy confirmed HCD biocompatible with mesoporous silica nanoparticles (MSNs) encapsulation resulted in a sustained release property in delivering HCD for the inhibition of DPP4 via the activity and protein levels of DPP4 analysis. In the enzymatic activity assay, MSN-HCD directly changed DPP4 activity. Moreover, MSN-HCD nanoparticles were treated with Caco-2 cells and the protein levels of DPP4 determined within the cells. The results revealed that MSN-HCD caused reduction of DPP4 activity in a time- and dose-dependent fashion. Orally administered MSN-HCD in diet-induced diabetic mice alleviated blood glucose via an oral glucose tolerance test. In addition, administration of MSN-HCD for five weeks revealed that the biochemical cues such as pyruvate transaminase (GPT), glutamate oxaloacetate transaminase (GOT), triglycerides (TG), cholesterol (CHO), and glycated hemoglobin (HbA1c) in mice were commendable as further confirmation of MSN-HCD efficacy and less adverse effects in down-regulation of hyperglycemia. Furthermore, this formulation effectively controlled blood glucose and significantly decreased the body weight of mice, suggesting that MSN-HCD exerts natural DPP4 inhibitor as a potential clinical drug for the treatment of diabetes.
机译:天然补品具有良好的疗效,且抗糖尿病治疗的不良反应较少,但是它们作为抗糖尿病药的进展在递送系统方面并不令人满意。二肽基肽酶4(DPP4)/ CD26)可以降解胰高血糖素样肽1(GLP-1),从而降低血糖水平。从长寿花提取的16-羟色胺酸-3,13-丁-16,15-内酯(HCD)具有许多降血糖潜力,包括潜在的降糖潜力。考虑到HCD的应用,生物利用度受低溶解度的影响。抗糖尿病功效的扩展实验证实了HCD与中孔二氧化硅纳米粒子(MSNs)包囊具有生物相容性,从而通过DPP4分析的活性和蛋白质水平在递送HCD抑制DPP4方面具有持续释放的特性。在酶活性测定中,MSN-HCD直接改变DPP4活性。此外,用Caco-2细胞处理了MSN-HCD纳米颗粒,并确定了细胞内DPP4的蛋白水平。结果表明,MSN-HCD以时间和剂量依赖性方式导致DPP4活性降低。在饮食诱导的糖尿病小鼠中口服MSN-HCD通过口服葡萄糖耐量试验减轻了血糖。此外,给予MSN-HCD 5周后发现,小鼠的生化线索包括丙酮酸转氨酶(GPT),谷氨酸草酰乙酸转氨酶(GOT),甘油三酸酯(TG),胆固醇(CHO)和糖化血红蛋白(HbA1c)值得进一步确认的MSN-HCD功效和对高血糖下调的不良影响较小。此外,该制剂可有效控制血糖并显着降低小鼠体重,这表明MSN-HCD发挥天然DPP4抑制剂作为治疗糖尿病的潜在临床药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号